Navigation Links
Roxane Laboratories, Inc. Announces the Launch of Perindopril Erbumine Tablets
Date:11/10/2009

COLUMBUS, Ohio, Nov. 10 /PRNewswire/ -- Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application (ANDA) for Perindopril Erbumine Tablets, 2mg, 4mg and 8mg by the U.S. Food and Drug Administration. The product is available in bottles of 100 for immediate shipment to wholesalers and pharmacies nationwide.

Roxane Laboratories' Perindopril Erbumine Tablets are AB rated to ACEON® (perindopril erbumine) tablets. Annual sales of ACEON® are approximately $24.1 Million(1).

Full prescribing information for Perindopril Erbumine Tablets is available on the Roxane Laboratories website at www.Roxane.com or upon request by calling Roxane Laboratories Technical Product Information at

1.800.962.8364.

About Roxane Laboratories, Inc.

Roxane Laboratories is located in Columbus, OH in a modern 500,000 square foot manufacturing and laboratory facility. The facility spans 70 acres and currently employs over 1,000 people. Currently, Roxane Laboratories markets over 80 medications in nearly 250 package sizes, focusing on an expanding line of Multisource pharmaceutical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled- release tablets; nasal sprays, cytotoxics and CII narcotics.

Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim

Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and approximately 41,300 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2008, Boehringer Ingelheim posted net sales of US $17 billion (11.6 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information on Boehringer Ingelheim, please visit http://us.boehringer-ingelheim.com.

(1) IMS MAT dollar sales ending 9/2009

ACEON® is a registered trademark of Solvay Pharmaceuticals, Inc.

SOURCE Roxane Laboratories, Inc.


'/>"/>
SOURCE Roxane Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Roxane Laboratories, Inc. Announces the Launch of Risperidone Oral Solution 1mg/mL
2. Roxane Laboratories, Inc. Announces the Launch of Levetiracetam Tablets and Oral Solution
3. Roxane Laboratories, Inc. Initiates a Nationwide Voluntary Recall of Two Manufacturing Lots of Sodium Polystyrene Sulfonate Suspension in the US and Puerto Rico
4. Roxane Laboratories, Inc. Announces the Approval of Morphine Sulfate Tablets and Oral Solution
5. Roxane Laboratories, Inc. Announces the Launch of Ramipril Capsules
6. Roxane Laboratories, Inc. Announces the Launch of Acarbose Tablets
7. Roxane Laboratories, Inc. Announces the Launch of Granisetron Hydrochloride Tablets, 1mg
8. Roxane Laboratories, Inc. Announces the Launch of Balsalazide Disodium Capsules, 750mg
9. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
10. Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation of Georges Ugeux from Board of Directors
11. Caraco Pharmaceutical Laboratories, Ltd. Announces Appointment of F. Folsom Bell to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... 2017 , ... VisualSP has helped over 1.5 million SharePoint users learn the ... installation of its Help System for SharePoint was at the farm level. Enterprises using ... tenant. , The company recently released a modified version of the Help System, ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... Technology™, is the first technology to directly address the resolution to globally reduce ... Technology™ is a patented compound of FDA and TTB approved ingredients that when ...
(Date:3/28/2017)... ... March 29, 2017 , ... ... pharmacist Dr. Isabella Wentz, Pharm.D., FASCP. The program was recently launched on March ... common questions regarding thyroid function. , Dr. Izabella Wentz is a licensed ...
(Date:3/28/2017)... San Mateo, CA (PRWEB) , ... ... ... Radiosurgery Society (RSS), a non-profit medical society dedicated to advancing the science ... manuscript leveraging data from its RSSearch Patient Registry, a multi-institutional, observational registry ...
(Date:3/28/2017)... ... 2017 , ... WHO: , Dr. Paul Thomas; Dr. Brian Hooker; Dr. Judy ... PhD scientists will speak to the press on behalf of over 200 doctors, scientists, ... vaccine safety commission. , WHERE: , Zenger Room, National Press Club, 529 14th ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017 NetworkNewsWire Editorial ... ... public safety in regulating marijuana, but economic arguments also favor ... and reduced law enforcement costs. However, to legalize and regulate ... by SinglePoint, Inc. (OTC: SING) ( SING Profile ), American ...
(Date:3/29/2017)... FinancialBuzz.com News Commentary  ... The U.S. could see significant economic benefits ... published by New Frontier Data, the legal cannabis market is projected ... legalization in the United States , as well ... a major factor that drives growth in this sector. Medical cannabis ...
(Date:3/28/2017)... 2017  Las Vegas ophthalmology practice, Center For Sight, ... (Allergan, Dublin ), an implant that ... reducing intraocular pressure in patients with moderate to severe ... by glaucoma that can lead to progressive optic nerve ... left untreated. According to the National Eye ...
Breaking Medicine Technology: